The makers of the Pfizer-BioNTech vaccine will quickly ask regulators for clearance to make use of it in youngsters 5 and older, and are on the point of make smaller doses of the vaccine for youthful youngsters, based on one of many founders of BioNTech, the German firm that developed the vaccine in partnership with Pfizer.
“We can be presenting the outcomes from our examine on 5-to-11-year-olds to authorities all over the world within the coming weeks,” Ozlem Tureci, the co-founder of BioNTech and its chief medical officer, advised Der Spiegel, a German information website, in an interview printed on Friday. She added that the corporate can be making use of for clearance of using the vaccine for that age group, together with in Europe.
Each the European Union and the US cleared the Pfizer vaccine to be used in youngsters 12 and over in Could. They haven’t cleared any coronavirus vaccines for youngsters youthful than 12.
Dr. Tureci, who based BioNTech together with her husband, Ugur Sahin, mentioned the businesses have been getting ready to make smaller doses of the vaccine in anticipation of clearance by authorities.
Dr. Sahin, who’s BioNTech’s chief government, urged anybody who’s eligible for vaccination to get their doses earlier than an anticipated wave of infections this fall.
“There are nonetheless about 60 days left for us as a society to keep away from a tricky winter,” he mentioned.